Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMMX 
Immix Biopharma Inc (IMMX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: IMMX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.97% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 120.25M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 1 | Beta 0.33 | 52 Weeks Range 1.34 - 4.05 | Updated Date 11/4/2025 |
52 Weeks Range 1.34 - 4.05 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -66.85% | Return on Equity (TTM) -162.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58002043 | Price to Sales(TTM) - |
Enterprise Value 58002043 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.37 | Shares Outstanding 33035515 | Shares Floating 19376811 |
Shares Outstanding 33035515 | Shares Floating 19376811 | ||
Percent Insiders 35.71 | Percent Institutions 8.46 |
Upturn AI SWOT
Immix Biopharma Inc
Company Overview
History and Background
Immix Biopharma Inc. is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer and other diseases. Founded in 2012, it has focused on Tumor-Specific Antibody-directed Onco-lytic Virus Immunotherapy (tHAV).
Core Business Areas
- Drug Development: Focuses on developing and commercializing therapeutics based on its Systemically Accessible ChemoTherapeutics (SACT) platform, including lead asset IMX-110.
Leadership and Structure
The company is led by Dr. Sean Senn as CEO. The structure includes research, development, and clinical operations teams.
Top Products and Market Share
Key Offerings
- IMX-110: IMX-110 is ImmixBio's lead product candidate, currently in Phase 1b/2a clinical trials for the treatment of advanced soft tissue sarcoma (STS). It combines doxorubicin with the company's proprietary SACT platform. There is no reliable market share data available as it is still in clinical trials. Competitors depend on the types of soft tissue sarcoma being treated, but include standard chemotherapy regimens, targeted therapies from companies like Eli Lilly (Lly) for example Olartumumab, and immune checkpoint inhibitors from companies like Merck (MRK) with Pembrolizumab.
Market Dynamics
Industry Overview
The oncology market is highly competitive and rapidly evolving, with significant investments in research and development. It is characterized by increasing demand for targeted therapies and personalized medicine.
Positioning
Immix Biopharma is positioned as a developer of novel targeted cancer therapies, focusing on addressing unmet needs in sarcoma and other difficult-to-treat cancers.
Total Addressable Market (TAM)
The global soft tissue sarcoma market is projected to reach approximately $5.7 billion by 2028. Immix Biopharma aims to capture a portion of this market with IMX-110.
Upturn SWOT Analysis
Strengths
- Proprietary SACT platform
- IMX-110 clinical trial progress
- Experienced management team
Weaknesses
- Limited financial resources
- Early stage clinical development
- High dependence on IMX-110 success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of SACT platform to other cancer types
- Positive clinical trial results driving valuation
Threats
- Clinical trial failures
- Competition from established cancer therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
- JNJ
Competitive Landscape
Immix Biopharma operates in a competitive landscape against larger pharmaceutical companies with established oncology franchises.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the early stage of the company.
Future Projections: Future growth is dependent on the successful development and commercialization of IMX-110 and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Advancing IMX-110 through clinical trials, exploring partnerships, and expanding its intellectual property portfolio.
Summary
Immix Biopharma is a high-risk, high-reward company focused on innovative cancer therapies. Its success hinges on the clinical development of IMX-110 and its proprietary platform. The company needs to secure partnerships and funding to navigate the challenging regulatory and competitive landscape. Investing now is betting on the possibility that the company has found a therapeutic that can treat soft tissue sarcoma where current alternatives aren't working well. The company's lack of revenue means that it is speculative and is subject to market sentiment as to whether it can fund itself forward.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immix Biopharma Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2021-12-16 | Co-Founder, CEO & Chairman Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://www.immixbio.com |
Full time employees 18 | Website https://www.immixbio.com | ||
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.